Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER)

Randomized Phase Ii

Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-18-0613 ◽

2018 ◽

Vol 24 (18) ◽

pp. 4380-4387 ◽

Cited By ~ 26

Author(s):

Maura N. Dickler ◽

Cristina Saura ◽

Donald A. Richards ◽

Ian E. Krop ◽

Andrés Cervantes ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Study ◽

Advanced Breast ◽

Phase II Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer

Case Medical Research ◽

10.31525/ct1-nct03939871 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Study ◽

Advanced Breast ◽

Oral Vinorelbine ◽

Abstract P6-12-01: Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis byPIK3CAandESR1mutation status from circulating tumor DNA

10.1158/1538-7445.sabcs16-p6-12-01 ◽

2017 ◽

Cited By ~ 2

Author(s):

MN Dickler ◽

C Saura ◽

M Oliveira ◽

DA Richards ◽

IE Krop ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Study ◽

Circulating Tumor Dna ◽

Advanced Breast ◽

Tumor Dna

Prevention of stomatitis in patients with hormone receptor–positive advanced breast cancer treated with everolimus plus exemestane: A phase II study of a steroid-based mouthwash.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps661 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS661-TPS661 ◽

Cited By ~ 1

Author(s):

Hope S. Rugo ◽

Mark Steven Chambers ◽

Jennifer Keating Litton ◽

Ingrid A. Mayer ◽

Jaqueline Willemann Rogerio ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Study ◽

Advanced Breast ◽

A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.520 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 520-520 ◽

Cited By ~ 18

Author(s):

Maura N. Dickler ◽

Cristina Saura ◽

Donald A. Richards ◽

Ian E. Krop ◽

Andres Cervantes ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Study ◽

Advanced Breast ◽

Pi3k Inhibitor ◽

PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer

Contemporary Clinical Trials Communications ◽

10.1016/j.conctc.2018.05.012 ◽

2018 ◽

Vol 10 ◽

pp. 190-192

Author(s):

Filipa Lynce ◽

Mervat Saleh ◽

Ayesha Shajahan-Haq ◽

Christopher Gallagher ◽

Asma Dilawari ◽

...

Keyword(s):

Breast Cancer ◽

African American ◽

Advanced Breast Cancer ◽

African American Women ◽

Phase Ii ◽

Hormone Receptor ◽

Advanced Breast ◽

Safety Study ◽

American Women ◽

346 Taxol or doxorubicin as first line chemotherapy in advanced breast cancer (ABC). A prospective randomized phase II study with crossover

European Journal of Cancer ◽

10.1016/0959-8049(95)95599-2 ◽

1995 ◽

Vol 31 ◽

pp. S75 ◽

Cited By ~ 1

Author(s):

R. Paridaens ◽

P. Bruning ◽

F. Calabresi ◽

A. Awada ◽

J.A. Roy ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Breast ◽

First Line ◽

Randomized Phase Ii ◽

Line Chemotherapy

Abstract P1-15-01: A randomized phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally-advanced hormone-receptor-positive breast cancer: First results

10.1158/0008-5472.sabcs13-p1-15-01 ◽

2013 ◽

Author(s):

N Quenel-Tueux ◽

F Dalenc ◽

T Bachelot ◽

M Pulido ◽

H Bonnefoi ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Study ◽

Locally Advanced ◽

Randomized Phase Ii ◽

First Results ◽

Positive Breast Cancer

Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)

10.1158/1538-7445.am2014-ct101 ◽

2014 ◽

Cited By ~ 23

Author(s):

Richard S. Finn ◽

John P. Crown ◽

Istvan Lang ◽

Katalin Boer ◽

Igor M. Bondarenko ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Breast ◽

Line Treatment ◽

Cyclin Dependent Kinase ◽

First Line ◽

Randomized Phase Ii ◽

First Line Treatment

Abstract OT3-02-04: Randomised phase II study evaluating, as first-line chemotherapy, single-agent oral vinorelbine administered with two different schedules in patients with hormone receptor positive, HER2-negative advanced breast cancer (TempoBreast-1 trial)

10.1158/1538-7445.sabcs15-ot3-02-04 ◽

2016 ◽

Cited By ~ 1

Author(s):

J De la Haba ◽

M Cazzaniga ◽

G Freyer ◽

L Costa ◽

E Petru ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Study ◽

Single Agent ◽

First Line ◽

Oral Vinorelbine ◽

Line Chemotherapy